Año: 2021
Journal Impact Factor (JIF): 17.5640
| Categoría | Edición | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|---|
| COMPUTER SCIENCE, ARTIFICIAL INTELLIGENCE | SCIE | 4/145 | Q1 | T1 | D1 |
| COMPUTER SCIENCE, THEORY & METHODS | SCIE | 1/110 | Q1 | T1 | D1 |
Año: 2021
Journal Citation Indicator (JCI): 4,230
| Categoría | Posición | Cuartil | Tercil | Decil | Percentil |
|---|---|---|---|---|---|
| COMPUTER SCIENCE, ARTIFICIAL INTELLIGENCE | 4/190 | Q1 | T1 | D1 | 98,16 |
| COMPUTER SCIENCE, THEORY & METHODS | 1/143 | Q1 | T1 | D1 | 99,65 |
Año:
2021
CiteScore:
28,400
| Categoría | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|
| Hardware and Architecture | 1/167 | Q1 | T1 | D1 |
| Information Systems | 3/353 | Q1 | T1 | D1 |
| Signal Processing | 1/115 | Q1 | T1 | D1 |
| Software | 4/398 | Q1 | T1 | D1 |
SJR año:
2021
Factor de Impacto:
4,557
| Categoría | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|
| Hardware and Architecture | 2/165 | Q1 | T1 | D1 |
| Information Systems | 4/383 | Q1 | T1 | D1 |
| Signal Processing | 2/112 | Q1 | T1 | D1 |
| Software | 7/381 | Q1 | T1 | D1 |
| Agencia | Código de Proyecto |
|---|---|
| AbbVie | - |
| Alzheimer's Association | - |
| Alzheimer's Disease Neuroimaging Initiative (ADNI), USA (National Institutes of Health) | U01 AG024904 |
| Alzheimer's Drug Discovery Foundation | - |
| Araclon Biotech | - |
| BioClinica, Inc. | - |
| Biogen | - |
| Bristol-Myers Squibb Company | - |
| Canadian Institutes of Health Research | - |
| CereSpir, Inc. | - |
| Cogstate | - |
| DOD ADNI, Spain (Department of Defense) | W81-XWH-12-2-0012 |
| Eisai Inc. | - |
| Elan Pharmaceuticals, Inc. | - |
| Eli Lilly and Company | - |
| EuroImmun | - |
| F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc. | - |
| Fujirebio | - |
| GE Healthcare | - |
| IXICO Ltd. | - |
| Janssen Alzheimer Immunotherapy Research & Development, LLC. | - |
| Johnson & Johnson Pharmaceutical Research & Development LLC. | - |
| Lumosity | - |
| Lundbeck | - |
| Merck Co., Inc. | - |
| Meso Scale Diagnostics, LLC. | - |
| MINECO/ FEDER, Spain | RTI2018-098913-B100; CV20-45250; A-TIC-080-UGR18 |
| Ministerio de Universidades, Spain under the FPU Predoctoral Grant | FPU 18/04902 |
| National Institute of Biomedical Imaging and Bioengineering | - |
| National Institute on Aging | - |
| NeuroRx Research | - |
| Neurotrack Technologies | - |
| Novartis Pharmaceuticals Corporation | - |
| Pfizer Inc. | - |
| Piramal Imaging | - |
| Servier | - |
| Takeda Pharmaceutical Company | - |
| Transition Therapeutics | - |
| # | Autor |
|---|---|
| 1 | |
| 2 | Jimenez-Mesa, C |
| 3 | Romero-Garcia, R |
| 4 | Segovia, F |
| 5 | Ramirez, J |
| 6 | Castillo-Barnes, D |
| 7 | Martinez-Murcia, FJ |
| 8 | Ortiz, A |
| 9 | Salas-Gonzalez, D |
| 10 | Illan, IA |
| 11 | Puntonet, CG |
| 12 | Lopez-Garcia, D |
| 13 | Gomez-Rio, M |
| 14 | Suckling, J |
